Rockfish Bio

Rockfish Bio is a preclinical-stage biotech focused on the burgeoning field of senolytics—therapies that clear senescent cells. The company's platform identifies compounds that exploit a metabolic vulnerability in senescent cells, offering a potentially safer and more targeted approach than first-generation senolytics. Its lead candidate, RFB01016, has shown promising preclinical results in extending healthspan and lifespan and reducing senescent cell burden across multiple tissues. The company is actively seeking funding to advance its pipeline and capitalize on the significant market opportunity in age-related diseases.

A discovery platform for senolytic drugs that targets a specific metabolic pathway unique to senescent cells. It generates both small molecule (IAAC-based) and mRNA-based therapeutic candidates designed to selectively eliminate senescent cells without harming healthy cells.

Rockfish Bio operates in the competitive senolytic/therapeutics space, which includes publicly traded companies like Unity Biotechnology and numerous private ventures such as Oisin Biotechnologies, Cleara Biotech, and Senolytic Therapeutics. Large pharma companies are also exploring the area through internal research and partnerships. Rockfish aims to differentiate itself through its specific focus on a metabolic pathway within senescent cells.